NKTX Stock Overview
A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Nkarta, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.91 |
52 Week High | US$16.24 |
52 Week Low | US$1.28 |
Beta | 0.84 |
11 Month Change | 12.72% |
3 Month Change | 0.58% |
1 Year Change | 240.39% |
33 Year Change | -78.82% |
5 Year Change | n/a |
Change since IPO | -85.57% |
Recent News & Updates
Recent updates
Nkarta: A Look Into Q1 Results And Upcoming Catalysts
May 23Nkarta: Down 50% Since March With A Clinical Catalyst Ahead
Apr 27Nkarta: NK Cell Therapy Advancement On Two Fronts
Mar 25Nkarta: Possible Upside From H1 Update, If Positive
Jan 25Here's Why We're Watching Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Jan 16We're Keeping An Eye On Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Oct 04We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Jun 21We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Mar 06Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation
Nov 20Nkarta GAAP EPS of -$0.61
Aug 11We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jun 09Nkarta: A Promising Natural Killer Cell Play
May 20We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
Aug 23Nkarta (NASDAQ:NKTX) Is In A Good Position To Deliver On Growth Plans
May 10Nkarta gets greenlight from the FDA for NKX019 cancer study
Apr 28We're Not Very Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Rate
Jan 25Shareholder Returns
NKTX | US Biotechs | US Market | |
---|---|---|---|
7D | 3.9% | 3.4% | -2.4% |
1Y | 240.4% | 17.1% | 17.5% |
Return vs Industry: NKTX exceeded the US Biotechs industry which returned 15.4% over the past year.
Return vs Market: NKTX exceeded the US Market which returned 17.2% over the past year.
Price Volatility
NKTX volatility | |
---|---|
NKTX Average Weekly Movement | 12.2% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NKTX's share price has been volatile over the past 3 months.
Volatility Over Time: NKTX's weekly volatility has decreased from 24% to 12% over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 150 | Paul Hastings | www.nkartatx.com |
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company’s lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors.
Nkarta, Inc. Fundamentals Summary
NKTX fundamental statistics | |
---|---|
Market cap | US$467.90m |
Earnings (TTM) | -US$116.20m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.2x
P/E RatioIs NKTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NKTX income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$116.20m |
Earnings | -US$116.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.65 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NKTX perform over the long term?
See historical performance and comparison